logo-loader
Mining
Tertiary Minerals PLC

Tertiary Minerals looking up again as fluorspar price rallies

One potential acquisition is at an advanced stage of talks

picture of fridge
Fluorspar is used in refrigeration

Tertiary Minerals PLC (LON:TYM) has issued a bullish assessment of prospects following an uptick in the fluorspar price and a recent strategic relationship with commodities group Possehl.

Richard Clemmey, managing director, said development progress had been slower than hoped due to delays in permitting at Storuman in Sweden, but its search for fluorspar project acquisitions had moved forward with one project now at an advanced stage of talks.

READ: Tertiary Minerals raises £500,000 via a placing to progress evaluation of acquisition opportunities, advance project work

The Possehl deal was also a critical building block for the company, he said.

“This strategic relationship not only provides us with the opportunity, and competitive advantage, to secure long-term sales contracts but also access to pre-financing once the definitive Offtake Agreement is signed as we move closer to mine development and production."

 "It is also pleasing to see the fluorspar market and prices improve during the latter part of 2017 and we look forward to this trend continuing,” he added.

Tertiary noted that its team at the MB project in Nevada received the Bureau of Land Management's (BLM) 2017 Hardrock Small Operator Award (National award) for outstanding and innovative reclamation and sustainable mineral development work on the project.

“As we head into 2018, with rekindled investor interest in the company, we have a number of irons in the fire,” Clemmey added.

Losses for the year to September were £395,000 (£473,000) on revenues of £241,000.

Quick facts: Tertiary Minerals PLC

Price: £0.00

Market: AIM
Market Cap: £1.35 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

N4 Pharma's Nuvec platform 'on a clear path' towards clinical trials

N4 Pharma PLC (LON:N4P) CEO Nigel Theobald speaks to Proactive London's Andrew Scott following the release of the firm's interim results to June 2019. He says it's been an incredibly active period for them where, among a number of developments, they've confirmed that Nuvec® works for both DNA...

16 minutes ago

2 min read